On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy.
Related Items
TOP - March 2023 Vol 16, No 2 published on March 14, 2023 in FDA Updates
TOP - January 2023 Vol 16, No 1 published on January 10, 2023 in FDA Updates
TOP - November 2022 Vol 15, No 6 published on November 9, 2022 in FDA Updates
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in FDA Updates
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in FDA Updates
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in FDA Updates
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in FDA Updates
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in FDA Updates
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in FDA Updates
TOP - October 2021 Vol 14, No 6 | Biosimilars published on November 5, 2021 in FDA Updates, Biosimilars
Last modified: February 22, 2023
